Cellular tumor antigen P53/TP53, Human (His-SUMO)
Based on 1 publication(s) in Google Scholar
The cellular tumor antigen P53/TP53 is a tumor suppressor that can induce growth arrest or apoptosis in a variety of tumor types. It regulates the cell cycle by negatively controlling genes critical for division. Cellular tumor antigen P53/TP53, Human (His-SUMO) is the recombinant human-derived Cellular tumor antigen P53/TP53, expressed by E. coli , with N-SUMO, N-6*His labeled tag.
- Species: Human
- Source: E. coli
-
Storage:Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Technical Parameters
-
Product Properties
- Documentation
- Help & FAQs
Biological Activity
Description
The cellular tumor antigen P53/TP53 is a tumor suppressor that can induce growth arrest or apoptosis in a variety of tumor types. It regulates the cell cycle by negatively controlling genes critical for division. Cellular tumor antigen P53/TP53, Human (His-SUMO) is the recombinant human-derived Cellular tumor antigen P53/TP53, expressed by E. coli , with N-SUMO, N-6*His labeled tag.
Background
Cellular tumor antigen P53/TP53 functions as a tumor suppressor across various tumor types, exhibiting the ability to induce growth arrest or apoptosis depending on the physiological context and cell type. Involved in cell cycle regulation, TP53 acts as a trans-activator that negatively regulates cell division by controlling a set of genes essential for this process. Its pro-apoptotic activity is mediated through the stimulation of BAX and FAS antigen expression or repression of Bcl-2 expression. TP53 induces apoptosis by interacting with PPP1R13B/ASPP1 or TP53BP2/ASPP2, and this activity is inhibited by PPP1R13L/iASPP. In cooperation with mitochondrial PPIF, TP53 participates in activating oxidative stress-induced necrosis, independent of transcription. It induces the transcription of long intergenic non-coding RNAs, such as lincRNA-p21 and lincRNA-Mkln1, which contribute to TP53-dependent transcriptional repression and apoptosis. Additionally, TP53 is implicated in Notch signaling cross-over, prevents CDK7 kinase activity in response to DNA damage, and regulates the circadian clock by repressing CLOCK-BMAL1-mediated transcriptional activation of PER2. Different isoforms of TP53 exhibit variations in transactivation activity, apoptosis induction, and growth suppression, showcasing the complexity of its regulatory functions.
Verified Bioactivity
1.Measured by its ability to enhance HCT116 cells survival during chronic starvation. The ED50 for this effect is 22.59 ng/mL, corresponding to a specific activity is 4.427×104 Unit/mg.
2.Measured by its binding ability in a functional ELISA. Immobilized Human MDM2 Protein at 2 μg/mL (100 μL/well) can bind Biotinylated Human TP53 Protein, The ED50 for this effect is 50-100 ng/mL.
MCE Validation Data
-
Purity - SDS-PAGE
Purity - SDS-PAGE
-
Bioactivity - Cell-Based Assay
Bioactivity - Cell-Based Assay
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep Med
KRASG12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC. [Abstract]2025 Feb 18;6(2):101966. PMID: 39970873
Technical Parameters
-
Species Human
-
Source E. coli
-
Tag N-SUMO;N-6*His
-
Accession
P04637 (M1-D393)
-
Molecular Construction
-
N-term
-
6*His-SUMO
-
TP53 (M1-D393)
Accession # P04637 -
C-term
-
-
Protein Length
Full Length
-
Synonyms
TP53; Mutant Tumor Protein 53; Tumor Protein P53; Li-Fraumeni Syndrome; P53; Tumor Supressor P53; Cellular Tumor Antigen P53; Tumor Protein 53; LFS1; P53-Ex10 Isoform; Tumor Suppressor P53; Truncated TP53; Phosphoprotein P53; Truncated P53; Antigen NY-CO-
-
AA Sequence
MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD
-
Predicted Molecular Mass
59.7 kDa
-
Molecular Weight
Approximately 66-75 kDa, based on SDS-PAGE under reducing conditions.
-
Purity
≥ 90%, as determined by reducing SDS-PAGE.
Product Properties
Lyophilized powder
1.Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4, 6% trehalose.
2.Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4, 8% trehalose.
3..Lyophilized from 0.22 μm filtered solution in 20 mM Tris-HCl, 0.5 M NaCl, 6% trehalose, pH 8.0.
Note: For SPR assay, please replace the buffer. Primary amine components (e.g., Tris, imidazole) can affect protein-coupled chips.
Please refer to the lot-specific COA for specific buffer information.
<1 EU/μg, determined by LAL method.
It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH2O.
Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Room temperature in continental US; may vary elsewhere.
Documentation
-
Data Sheet (239 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz
